$BEAM

Beam Therapeutics sued former scientist Emma Wang, alleging she stole trade secrets to found Chinese startup YolTech, which is developing a rival treatment for AATD. Beam claims Wang used stolen information to file patents while still employed. YolTech later licensed its treatment to Serapha.

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).

ARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.

Cathie Wood's Ark Invest added to positions in Meta Platforms (META), Airbnb (ABNB), and Beam Therapeutics (BEAM). Meta's stock surged 11% on Monday, with Wells Fargo raising its price target to $796. Airbnb is up 31% year-over-year, despite industry challenges. Beam Therapeutics fell 10% after mixed clinical trial data, but remains in pursuit of accelerated approval for BEAM-302.

ARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.

Beam Therapeutics (BEAM) reported Phase 1/2 results for BEAM-302, showing increased AAT levels in patients with alpha-1 antitrypsin deficiency. At 60 mg, mean AAT rose from 5.0 to 14.4 micromolar, exceeding the protective threshold. The company is pursuing pivotal development with a plan for accelerated approval.

Cathie Wood's Ark Invest sold shares of Palantir (PLTR) and AMD (AMD), and bought shares of Robinhood (HOOD) and Cerebras (CBRS). The trades were valued at $6.5M, $9.9M, $3.2M, and $6.5M respectively. Palantir and AMD saw recent partnerships and strong earnings, while Robinhood and Cerebras have seen market volatility.

Beam Therapeutics (BEAM) appointed Eric Foster as chief commercial officer. Foster will lead the company's commercial strategy as it advances candidates in hematology and genetic diseases. Beam is a biotech focused on precision genetic medicines.

Beam Global reported a 174% sequential revenue increase in Q2 2026, driven by backlog conversions. The company diversified into global energy, mobility, and intelligence sectors, with Europe matching U.S. revenue. Battery business gained traction in drones, robotics, and defense. Yuma relocation cut costs. Management expects margin expansion, targets AI data centers, and focuses on recurring revenue models. The company remains debt-free with a $100M credit line. Q2 gross margin improved by 30 pe